14/04/2026
PANS/PANDAS used to be described as “controversial.” And at the time, that was a fair reflection of the evidence we had.
But the literature has moved on.
The research has moved beyond simply describing a cluster of behaviours and we’re now starting to see clear biological signals emerging in the literature, that can’t be ignored.
A recent paper in Molecular Psychiatry is a good example of this:
Han, V. X., et al. (2025). Epigenetic, ribosomal, and immune dysregulation in paediatric acute-onset neuropsychiatric syndrome. Molecular Psychiatry, 30, 5389–5404. https://doi.org/10.1038/s41380-025-03127-5
In this study, children with PANS had normal results on routine testing. But when they looked more closely - using RNA sequencing - a different picture emerged.
They found:
– Dysregulation across ribosomal, epigenetic, and immune pathways
– Altered immune responsiveness
– Distinct gene expression profiles separating these children from controls
And importantly, these abnormalities moved to more typical patterns following treatment with IVIG.
This paper is important because it helps us to understand that PANS is a measurable biological phenotype - even when standard investigations come back “normal.”
Then when you layer in the treatment studies, the picture becomes harder to dismiss. Here are just a handful – there are more out there:
– A double-blind, randomised placebo-controlled trial found azithromycin was associated with improvements in OCD symptoms in acute-onset presentations (PANS)
https://doi.org/10.1089/cap.2016.0190
– IVIG has been associated with reductions in pro-inflammatory immune markers alongside improvements in neuropsychiatric symptoms in PANS https://doi.org/10.3389/fimmu.2024.1383973
– At a cellular level, immune and ribosomal pathway abnormalities appear to normalise following IVIG in children with PANS. https://doi.org/10.1212/NXI.0000000000200467
–Epigenetic and immune pathway changes in PANS were observed post CBD oil treatment, moving to more typical patterns Keating, B. A., et al. (2026). Neurotherapeutics
Is there more work to be done? Of course. But are we still in a place where PANS can be dismissed as “controversial”? I don’t think so.
Because at the centre of this are children whose lives are changed overnight. Children who are full of potential, who suddenly lose the ability to do the simple everyday things they could previously manage - while we continue to debate the label.
If you’re a clinician still holding onto the idea that PANS is too controversial to investigate or treat…
It might be time to take another look at the evidence.